Castle Biosciences Reports Second Quarter 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 70c
August 8, 2022 4:55 PM EDTCastle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of ($0.06), $0.70 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $34.84 million versus the consensus estimate of $28.37 million.
For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.
... More